Background {#Sec1}
==========

Uveitis in pediatric rheumatic diseases is identified as an inflammatory event of the uvea of the iris, choroid, and retina. Although rheumatic diseases are partially common during childhood, the rheumatic disease-related uveitis is an uncommon finding in young people accounting for approximately5 to 10% of all individuals with uveitis \[[@CR1], [@CR2]\]. Despite its low prevalence, potential complications of uveitis as well as high disease burden present the disease management as a considerable challenge. Although uveitis, due to rheumatic diseases, may be easily diagnosed, the effective treatments of this event remain limited owing to serious systemic side effects \[[@CR3]\]. More importantly, delay of diagnosis and treatment may lead to irreversible consequences like severe vision loss \[[@CR4]\]. In this review, we systematically assessed the epidemiological, etiological and managerial aspects of uveitis in pediatric rheumatic diseases.

Materials and methods {#Sec2}
=====================

Search strategy: This study was conducted according to the previous established methods and in compliance with the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) \[[@CR5]\]. The manuscript databases, including Medline, Web of Knowledge, Google Scholar, Scopus, and Cochrane were searched for any eligible studies in association with "Uveitis", "Rheumatology", and "pediatrics". The studies were restricted to those written in English. The inclusion criteria were the epidemiology, etiologies, and the treatments of uveitis in pediatric rheumatic diseases. The exclusion criteria were introduced as follows: a lack of clear and reproducible results, non-English studies, lack of access to the full text manuscript, case reports, case series, and review papers.

Data abstraction and validity assessment: Data abstraction was independently performed by two un-blinded reviewers on the structure collection forms without divergences in data collection. The study quality was evaluated based on the following criteria: 1) the systematic review and meta-analysis based on the questions primarily described and formulated; 2) inclusion and exclusion criteria predefined in the studies as eligibility criteria; 3) searching the literature performed on a systematic and comprehensive approach; 4), the full texts of the article dually reviewed to minimize the bias 5) the quality of included studies independently rated by the reviewers for appraising internal validity 6) the comprehensive list of studies' characteristics and findings7) the list of publication and risk of bias8) the assessment of heterogeneity \[[@CR6]\]. The present study aimed to determine the global prevalence, causes and new therapies of rheumatoid arthritis in children by determining the prevalence as well as the odds ratio in the relationship between the major risk factors and disease risk. Furthermore, the year of publishing, number of included patients, and the method of design were pointed.

Statistical analysis: Dichotomous variables are reported as proportions and percentages, and continuous variables as mean values. Binary outcomes from individual studies were to be combined with both Mantel-Hansel fixed effect models. The odds ratio (OR) and 95% confidence interval (CI) were used as concise statistics to compare the dichotomous variables. Cochran's Q test was used to determine the statistical heterogeneity of this study. This test was complemented with the I^2^ statistic quantifying the proportion of total variation across studies due to heterogeneity rather than chance. A value of I2 of 0--25% indicates insignificant heterogeneity, 26--50% low heterogeneity, 51--75% moderate heterogeneity, and 76--100% high heterogeneity. The publication bias was assessed by the rank correlation test and it was confirmed by the funnel plot analysis. The reported values were two-tailed, and hypothesis testing results were considered statistically significant at *p* = 0.05. Statistical analysis was conducted using the Stata software (version 13.1, Stata Corp, College Station, TX, USA).

Results {#Sec3}
=======

Prevalence and other epidemiological aspects of uveitis in pediatric rheumatic diseases {#Sec4}
---------------------------------------------------------------------------------------

To assess different epidemiological aspects of uveitis in pediatric rheumatic diseases based on the applied keywords,19 out of 128 studies focused on the different epidemiological aspects of uveitis in pediatric rheumatic diseases and 4 were excluded due to lack of adequate information, and 2 were excluded due to lack of full text, or review article in nature. Finally, 13 studies published between 1997 and 2017 met the endpoints that were analyzed \[[@CR7]--[@CR19]\] (Table [1](#Tab1){ref-type="table"}). Table 1The details of the studies on the prevalence and determinants of uveitisAuthor, yearNumberM/FAge at onsetRheumatic dis.Prevalence of UveitisPredictors of uveitisComplications of uveitisNordal, 2017 \[[@CR7]\]435149/2865.5JIA89 (20.5)age \< 7 years at JIA onset AHA \> 15 U/ml ANASardar, 2017 \[[@CR8]\]10210/10210.0Behçet's15 (15.0)synechiae, cataract, and macular edemaKahwage, 2017 \[[@CR9]\]8521/711.2cSLE7 (0.8)Fever, lymphadenopathyCecchin, 2017 \[[@CR10]\]27450/22411.5JIA57 (20.8)HypomobilityAngeles, 2015 \[[@CR11]\]28782/2056.5JIA52 (18.0)younger age oligoarticular subtypeBlindnessAngeles, 2013 \[[@CR12]\]498311.4JIA459 (11.6)female sex early age of arthritis onset, oligoarticular subtypeClarke, 2013 \[[@CR13]\]7942/379.0JIA18 (22.8)Shen, 2013 \[[@CR14]\]29288/1079.5JIA19 (6.7)Reininga, 2008 \[[@CR15]\]153JIA27 (17.6)Visual loss, glaucoma, cataract, posterior synechiae, cystoid macular oedema and papillitisGrassi, 2007 \[[@CR16]\]30965/1794.9JIA62 (20.1)early age of arthritis onset ANA DRB1\*11Heiligenhaus, 2005 \[[@CR17]\]3271JIA392 (12.0)early age of arthritis onset female gender ANAband keratopathy, posterior synechiae, cataract, glaucoma, and macula oedemaChalom, 1997 \[[@CR18]\]760JIA74 (9.3)early age of arthritis onsetsynechiae, band keratopathy, cataract, or glaucomaAkduman, 1997 \[[@CR19]\]78JIA7 (9.0)Visual loss band keratopathy and cataract

In total, 11,875 patients were assessed indicating a higher rate of uveitis in female than in male children. The average age of the patients at the beginning of uveitis was 8.8 years. Of 13 patients focused uveitis in pediatric rheumatic diseases, most of them (11 out of 13 manuscripts) included children suffering Juvenile Idiopathic Arthritis (JIA), while Behçet^,^s disease-related uveitis was assessed in one study and Systemic Lupus Erythematosus (SLE-related) uveitis in another. Initially considering studies focused on JIA-related uveitis yielded a pooled prevalence of11.8% (95%CI: 11.2 to 12.4%) for uveitis following JIA (Fig. [1](#Fig1){ref-type="fig"}). In this regard, the prevalence rate of uveitis related to Behçet^,^s disease and SLE was estimated to be 15.0 and 0.8%, respectively. The main predictors of uveitis in children suffering from rheumatic diseases were female gender, age \< 7 years at the onset of JIA (particularly in girls), oligoarticular subtype of disease and positive antinuclear antibody (ANA) \> 15 U/ml. ANA is positive in 70 to 90% those with uveitis. In this regard, poly-articular RF-positive subtype of JIA was revealed to be protective of uveitis. Reviewing the literature showed a strong racial tendency to uveitis in pediatric rheumatic diseases, so that the possibility of JIA-related uveitis in caucasian white children was nearly twice as much as African-American children. Regarding uveitis-related complications, the common complications encompassed band keratopathy (15.7 to 29%), synechiae (27 to 33%), cataract (8 to 31%), macular edema (6 to 25%), ocular hypertension/glaucoma (8 to 19%), and macular fibrosis (4%). Overall, complications of uveitis developed in 35.5 to 67% of children that one-third of them were present at diagnosis. Final visual acuity less than 20/50 was found in 11 to 31% and less than 20/200 in 12% of eyes, but blindness widely occurred from 0 to 17.5% in the affected children that was more common in African American children than in Caucasian children. The risk to vision is higher if JIA begins in the preschool years. To determine the overall prevalence of JIA-related uveitis, the statistical heterogeneity was significant with an I^2^ of 93.771% (*P* \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}). There was a significant publication bias as evidenced by either funnel plot asymmetry or the Egger test (*P* = 0.026). Fig. 1Prevalence of JIA-related uveitis. Our meta-analyses yielded a pooled prevalence of11.8% (95%CI: 11.2 to 12.4%) for uveitis following JIA. To determine overall prevalence of JIA-related uveitis, the statistical heterogeneity was significant with an I^2^ of 93.771% (*P* \< 0.001)

Pathophysiology of uveitis in pediatric rheumatic diseases {#Sec5}
----------------------------------------------------------

At the beginning of the last century, the eye manifestations of rheumatic diseases, especially in children with JIA had been well described. Since then, numerous cases of JIA-related uveitis have been reported. Formerly, many cases might have been missed in diagnosis, particularly asymptomatic patterns leading to high rates of visual loss; however, by advancing diagnostic approaches, this event is now rarely reported. The nature of rheumatic disease-related uveitis is mostly insidious at the onset and in some cases may be followed by a remitting course. Both eyes are mostly affected. In many cases, uveitis is non-granulomatous with a faint flare. In mild cases, Keratic precipitates can be seen in the inferior half of the corneal endothelium progressed to the anterior vitreous in severe cases with spreading inflammation to the posterior parts of the eye. Most changes have been identified to be linked to Human Leukocyte Antigen B27 (HLA B27) as one of the main markers for arthritis.

Naturally, uveitis is more commonly discovered in children with oligoarthritis and more rarely in systemic-onset arthritis. JIA-related uveitis more commonly occurs earlier in females than in males, a difference, which has not been exclusively explained. Although 90% of uveitis cases are revealed within the first 4 years of arthritis, it may sometimes occur in the first 7 years after onset of arthritis.

The pathogenesis of JIA and its associated uveitis is unknown. It is presumed to be autoimmune in nature. Genetically, histocompatibility allele profiles have been widely assessed, and higher expression of some HLA alleles such as DRB1\*1104 andDRB1\*01 was found in those with uveitis emphasizing the autoimmune nature of disease. Furthermore, the positivity of ANA in most cases also emphasizes this fact. Additionally, immune complex deposition has a potential place in the pathogenesis of uveitis, but the details of autoimmunity and specific autoantibodies in pathogenesis of uveitis are under investigation.

Recent advances in the treatment of uveitis in pediatric rheumatic diseases {#Sec6}
---------------------------------------------------------------------------

Table [2](#Tab2){ref-type="table"} summarizes different medical therapeutic approaches to uveitis in pediatric rheumatic diseases. Formerly, two groups of drugs, including glucocorticoids and nonbiologic Disease-Modifying Anti Rheumatic Drugs (DMARDS), were widely used to improve uveitis; however, by developing biological agents, these medications have been considered particularly. To evaluate the efficacy, response rates and complications of any old and novel drugs based on the applied keywords, of total 157 studies initially conducted, 42 studies published between 1998 and 2017 focused on different medications against uveitis (Table [2](#Tab2){ref-type="table"}. At the end of document text file). Table 2The details of the studies on the response to different therapeutic regimensAuthor, yearType of studyDiseaseNumberMedicationResponse rateCorrell, 2017 \[[@CR20]\]Review chartJIA60Adalimumab80.0%Horneff, 2016 \[[@CR21]\]Review chartJIA236Adalimumab61.0%Castiblanco, 2016 \[[@CR22]\]Review chartJIA14Adalimumab77.0%Henderson, 2016 \[[@CR23]\]cohort studyJIA92Adalimumab68.0%Klotsche, 2016 \[[@CR24]\]cohort studyJIA320Adalimumab77.0%Schmeling, 2014 \[[@CR25]\]Review chartJIA289Adalimumab63.4%García, 2013 \[[@CR26]\]Clinical trialJIA39Adalimumab60.0%Lerman, 2013 \[[@CR27]\]Review chartJIA56Adalimumab75.0%Simonini, 2013 \[[@CR28]\]Clinical trialJIA, Behçet's14Adalimumab57.4%Zannin, 2013 \[[@CR29]\]Cohort StudyJIA108Adalimumab67.4%Trachana, 2011 \[[@CR30]\]Cohort StudyJIA9Adalimumab65.4%Tynjälä, 2008 \[[@CR31]\]Review chartJIA20Adalimumab65.0%Gallagher, 2007 \[[@CR32]\]case seriesJIA23Adalimumab77.0%Vazquez, 2006 \[[@CR33]\]Clinical trialJIA9Adalimumab80.8%Sardar, 2017 \[[@CR8]\]Review chartJIA56Infliximab80.0%Aeschlimann, 2017 \[[@CR34]\]Review chartJIA52Infliximab60.0%Aeschlimann, 2014 \[[@CR35]\]Review chartJIA82Infliximab57.0%Tambralli, 2013 \[[@CR36]\]Review chartJIA95Infliximab74.1%Zannin, 2013 \[[@CR29]\]Review chartJIA48Infliximab42.8%Tugal, 2008 \[[@CR37]\]Review chartJIA20Infliximab80.0%Ardoin, 2007 \[[@CR38]\]Case seriesJIA16Infliximab79.0%de Oliveira, 2007 \[[@CR39]\]Review chartJIA30Infliximab70.0%Tynjälä, 2007 \[[@CR40]\]Review chartJIA21Infliximab31.0%Rajaraman, 2006 \[[@CR41]\]Review chartJIA6Infliximab100%Saeed, 2014 \[[@CR42]\]Review chartJIA9Etanercept66.7%Foeldvari, 2007 \[[@CR43]\]Review chartJIA34Etanercept70.0%Tynjälä, 2007 \[[@CR40]\]Review chartJIA45Etanercept31.0%de Oliveira, 2007 \[[@CR39]\]Review chartJIA9Etanercept70.0%Horneff, 2016 \[[@CR21]\]Review chartJIA94Etanercept68.0%Quesada, 2017 \[[@CR44]\]Review chartJIA89Tocilizumab46.0%Horneff, 2016 \[[@CR21]\]Review chartJIA74Tocilizumab61.0%Tappeiner, 2016 \[[@CR45]\]Review chartJIA17Tocilizumab58.8%Miserocchi, 2016 \[[@CR46]\]Review chartJIA8Rituximab75.0%Gallagher, 2007 \[[@CR32]\]Review chartJIA23Daclizumab80.0%Henderson, 2016 \[[@CR23]\]cohort studyJIA92Methotrexate76.0%Saeed, 2014 \[[@CR42]\]Review chartJIA147Methotrexate34.0%Marvillet, 2009 \[[@CR47]\]Review chartJIA75Methotrexate17.4%Papadopoulou, 2013 \[[@CR48]\]Review chartJIA254Methotrexate33.9%Kalinina, 2011 \[[@CR49]\]Review chartJIA22Methotrexate82.0%Heiligenhaus, 2007 \[[@CR50]\]Review chartJIA31Methotrexate41.9%Shetty, 1999 \[[@CR51]\]Review chartJIA4Methotrexate50.0%Weiss, 1998 \[[@CR52]\]Review chartJIA7Methotrexate85.7%

Of 42 studies, 34 focused on biological agents (Adalimumab in 14 studies, Infliximab in 10 studies, Etanercept in 5 studies, Tocilizumab in 3 studies, Rituximab in 1 study and Daclizumab in 1 study). In addition, Methotrexate as a common used DMARD for uveitis was assessed in 8 studies. Totally, the efficacy of Adalimumab was assessed in 1289 patients. The pooled response rate to Adalimumab was estimated to be 68.0% (95%CI: 65.4 to 70.6%). The drug-related side effects were recorded in the wide range of 3 to 52%, including non-ocular complications (e.g. autoimmune diseases, local pain, anemia, depression, abscess and even sepsis) and ocular complications (e.g. cataracts, and uveitis flares). However, they were mostly tolerable with the patients. In assessing the studies on the efficacy of Adalimumab, the statistical heterogeneity was significant with an I^2^ of 57.164% (*P* = 008) (Fig. [2](#Fig2){ref-type="fig"}). There was no significant publication bias as evidenced by either funnel plot asymmetry or the Egger test (*P* = 0.576). Fig. 2The efficacy of Adalimumab to treat JIA-related uveitis. The efficacy of Adalimumab was assessed in 1289 patients. The pooled response rate to Adalimumab was estimated to be 68.0% (95%CI: 65.4 to 70.6%). Assessment of the studies on the efficacy of Adalimumab indicated that the statistical heterogeneity was significant with an I^2^ of 57.164%

To determine the efficacy of Infliximab, 476 patients were examined for the medications leading to a pooled response rate of64.7% (95%CI: 59.8 to 69.3%). The most common side effects of the medications were the reactivation of uveitis and infusion reaction in approximately two-third of the patients, infectious events, vitreous hemorrhage, and systemic infections. In this regard, the statistical heterogeneity was also significant with an I^2^ of 73.066% (*P* \< 0.001) (Fig. [3](#Fig3){ref-type="fig"}). There was no significant publication bias (*P* = 234). Fig. 3The efficacy of Infliximab to treat JIA-related uveitis. To determine the efficacy of Infliximab, 476 patients were tested for the medications leading to a pooled response rate of 64.7% (95%CI: 59.8 to 69.3%). In this regard, the statistical heterogeneity was also significant with an I^2^of 73.066% (*P* \< 0.001). There was no significant publication bias (*P* = 234)

Given the efficacy of Etanercept, 516 patients were examined for this drug leading to pooled drug efficacy in 65.2% (95%CI: 60.9 to 69.2%). The most common side effects of this drug were infections and in some cases drugs intolerability. The documents to systematically assess other biological medications such as Tocilizumab and Rituximab were inadequate, but the mean response rates for these drugs were 59 and 75%, which required more investigation. The statistical heterogeneity was significant with an I^2^ of 81.342% (*P* \< 0.001) (Fig. [4](#Fig4){ref-type="fig"}). There was also no significant publication bias (*P* = 0.234). Fig. 4The efficacy of Etanercept to treat JIA-related uveitis. Respecting the efficacy of Etanercept, 516 patients were examined for this drug leading to pooled drug efficacy in 65.2% (95%CI: 60.9 to 69.2%). The statistical heterogeneity was significant with an I^2^ of 81.342% (*P* \< 0.001). There was also no significant publication bias (*P* = 0.234)

Of DMARDs, only Methotrexate was exclusively evaluated. In this regard, we systematically reviewed 8 studies consisted of 632 patients and could show a pooled response rate of40.0% (95%CI: 36.0% to 44.2) to Methotrexate. The statistical heterogeneity was also significant with an I^2^ of 91.314% (*P* \< 0.001) (Fig. [5](#Fig5){ref-type="fig"}). There was also a significant publication bias (*P* = 0.016). Fig. 5The efficacy of Methotrexate to treat JIA-related uveitis. To determine the efficacy of Methotrexate, we systematically reviewed 8 studies consisted of 632 patients and could show a pooled response rate of40.0% (95%CI: 36.0% to 44.2) to Methotrexate. The statistical heterogeneity was also significant with an I^2^ of 91.314% (*P* \< 0.001). There was also a significant publication bias (*P* = 0.016)

Discussion {#Sec7}
==========

In our systematic review, we attempted to consider uveitis sourced from all types of pediatric rheumatic diseases. Nevertheless, previous studies mostly focused on children with JIA, which is the most frequent cause for uveitis and the most important rheumatic disease with extra-articular signs. Epidemiologically, owing to differences in the type of studies, the geographical area as well as the different criteria for determining uveitis between 11.6 and 30.0% \[[@CR53], [@CR54]\], the prevalence of uveitis associated with JIA was varied. However, our meta-analyses yielded a pooled prevalence of 11.8% (95%CI: 11.2 to 12.4%) for uveitis following JIA, which is close to the lower limit of the prevalence published in the literature. There seems to be a decreasing incidence of uveitis due to early detection and selection of appropriate, preventive, and therapeutic regimens. In the current systematic review, we also examined potential risk factors for uveitis in pediatric rheumatic disease: female gender, age \< 7 years at the onset of JIA (particularly in girls), oligoarticular subtype of JIA and positive ANA. To put it differently, a combination of both clinical and laboratory markers can be employed to predict the possibility of uveitis in pediatric rheumatic diseases. In the literature, the main indicators for uveitis include female gender, category of JIA, particularly oligoarticular disease, younger age of onset, positive ANA, and HLA-B27 \[[@CR55], [@CR56]\]. It should be noted that the role of ethnicity in predicting uveitis remained uncertain. Given the clinical features and complications of childhood rheumatoid uveitis, keratopathy, synechiae, cataract, macular edema, ocular hypertension/glaucoma, and macular fibrosis were the main clinical features of this disease. In general, between one-third and two-third of patients suffer from these manifestations, albeit in cases with delayed diagnosis, severe visual loss and even blindness are expected.

The development of new biological drugs could make JIA-associated uveitis a controllable and early-diagnosed disease over the last decade. Particularly, introduction of TNF-inhibitors could successfully control disease poor prognosis. Our review had the highest concentrations of Adalimumab and Infliximab in the management of uveitis in these patients with a response rate of 68.0 and 64.7%, which appeared to be somewhat acceptable. In this regard, it seems that a combination of biological drugs with other subgroups of drugs such as DMARDs and even glucocorticoids may have been beneficial to achieve a complete recovery under these drugs. The potential side effects and clinical limitations of such drugs should also be considered. Although this review could show higher response rates to some other biological-based drugs such as Tocilizumab and Rituximab as 59 and 75%, respectively, a few studies focused on the effectiveness of these drugs; therefore, the clinical efficacy and their potential side effects were unclear. In general, the results demonstrated the high efficacy and safety of biological agents, especially Adalimumab.

As an important finding, reviewing the studies assessed the efficacy of biological agents reaching the overall responses with a low standard deviation and indicating the correctness of the study design, drug dosages used, and homogeneity of sampling selected for the studies. However, in evaluated studies of DMARDs, especially methotrexate, various responses to medications (33.9 to 85.7%) have been reported. In fact, this variety of response rate might be a reason for the low efficacy of these types of drugs for pediatrics. In addition, the necessity for discontinuing drugs and changing them to other drug families may be considered. We could show significant publication bias in those studies focused on DMARDs. The publication bias in medical journals refers to the publication of more articles containing positive conclusions or significant statistical results. This bias suggests that articles containing negative or non-significant statistical results are less likely to be published. The first cause of this bias is that the researchers themselves do not intend to report their negative or non-significant statistical results. Moreover, some organizations that provide funding for medical research may refuse to publish such findings or, at least, delay publication. Thus, the results published on the efficacy of some drugs such as DMARDs on pediatric uveitis might be unreliable, as they require predesign and pre-implementation.

Conclusion {#Sec8}
==========

In this systematic review, we attempted to consider uveitis originated from all types of pediatric rheumatic diseases. However, JIA, especially oligoarticular subtype of disease (positive ANA). is the most frequent cause of uveitis. This study showed the highest efficacy of Adalimumab and Infliximab in the management of uveitis. The efficacy of some drugs such as Tocilizumab and Rituximab showed moderate to high responses, respectively, and few studies focused on the effectiveness of these drugs; therefore, the clinical efficacy and their potential side effects were unclear. In general, the results summarize the efficacy and safety of biological agents, particularly Adalimumab. In the evaluated studies of DMARDs, especially methotrexate, mild to moderate responses have been reported.
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:   Antinuclear antibody

CI
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:   Disease Modifying Anti-Rheumatic Drugs
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:   Juvenile Idiopathic Arthritis

OR
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:   Preferred Reporting Items for Systematic review and Meta-Analysis Protocols
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:   Systemic Lupus Erythematosus
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